Teriparatide as a Systemic Treatment for Lower Extremity Nonunion Fractures: A Case Series |
| |
| Institution: | 1. From the Division of Endocrinology and Diabetes, The Children’s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;2. From the Orthopaedic Trauma & Fracture Service, Hospital of the University of Pennsylvania Department of Orthopaedic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;3. From the Ralston-Penn Clinic for Osteoporosis & Related Bone Disorders, Center for FOP and Related Bone Disorders, Departments of Medicine & Orthopaedic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.;1. Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY, USA;2. Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA;3. Hospital for Special Surgery, New York, NY, USA;4. Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA;1. From the Department of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, Virginia;2. From the Department of Endocrinology and Metabolism McGuire Veterans Affairs Medical Center, Richmond, Virginia.;1. From the Department of Otolaryngology - Head and Neck Surgery, Augusta, Georgia.;2. From the Department of Biostatistics and Epidemiology, Georgia Regents University, Augusta, Georgia.;1. Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA;2. Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA;3. Center of Bone Disease, Bone and Joint Department, Lausanne University Hospital, Lausanne, Switzerland |
| |
| Abstract: | ObjectiveTo investigate the effect of teriparatide (parathyroid hormone 1-34]) on the healing of long bone nonunion fractures.MethodsWe performed a retrospective chart review of patients with fracture nonunion, aged 10 to 99 years who were treated with teriparatide at the Children’s Hospital of Philadelphia or the Hospital of the University of Pennsylvania between November 2002 and January 2013. The primary endpoints were radiographic evidence of callus formation and fracture union, ability to bear weight without affected limb limp, and normal range of motion and strength.ResultsSix patients aged 19 to 64 years with tibial or femoral fractures that had not healed for 3 to 36 months were treated with teriparatide 20 μg/day. Accelerated healing of fracture nonunion was confirmed in 5 of 6 patients with time to complete union of 3 to 9 months. The shortest time to recovery was observed in younger patients without comorbidities. Treatment was well tolerated.ConclusionTeriparatide is a promising treatment for nonunion fractures, but its response depends on associated comorbidities. The potential benefit of teriparatide as an adjunct to treat nonunion justifies randomized placebo-controlled trials to determine its efficacy and safety in broader populations. (Endocr Pract. 2015;21:136-142) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
